key: cord-0898756-mzcpbrhe
authors: Chen, Pin-Shern; Hsu, Hui-Ping; Phan, Nam Nhut; Yen, Meng-Chi; Chen, Feng-Wei; Liu, Yu-Wei; Lin, Fang-Ping; Feng, Sheng-Yao; Cheng, Tsung-Lin; Yeh, Pei-Hsiang; Omar, Hany A.; Sun, Zhengda; Jiang, Jia-Zhen; Chan, Yi-Shin; Lai, Ming-Derg; Wang, Chih-Yang; Hung, Jui-Hsiang
title: CCDC167 as a potential therapeutic target and regulator of cell cycle-related networks in breast cancer
date: 2021-01-10
journal: Aging (Albany NY)
DOI: 10.18632/aging.202382
sha: 36079742b4acaa8bf491839982cb5a47c5538a65
doc_id: 898756
cord_uid: mzcpbrhe

According to cancer statistics reported in 2020, breast cancer constitutes 30% of new cancer cases diagnosed in American women. Histological markers of breast cancer are expressions of the estrogen receptor (ER), the progesterone receptor (PR), and human epidermal growth factor receptor (HER)-2. Up to 80% of breast cancers are grouped as ER-positive, which implies a crucial role for estrogen in breast cancer development. Therefore, identifying potential therapeutic targets and investigating their downstream pathways and networks are extremely important for drug development in these patients. Through high-throughput technology and bioinformatics screening, we revealed that coiled-coil domain-containing protein 167 (CCDC167) was upregulated in different types of tumors; however, the role of CCDC167 in the development of breast cancer still remains unclear. Integrating many kinds of databases including ONCOMINE, MetaCore, IPA, and Kaplan-Meier Plotter, we found that high expression levels of CCDC167 predicted poor prognoses of breast cancer patients. Knockdown of CCDC167 attenuated aggressive breast cancer growth and proliferation. We also demonstrated that treatment with fluorouracil, carboplatin, paclitaxel, and doxorubicin resulted in decreased expression of CCDC167 and suppressed growth of MCF-7 cells. Collectively, these findings suggest that CCDC167 has high potential as a therapeutic target for breast cancer.

Based on cancer statistics, about 30% of newly diagnosed cancers in the US are breast cancers [1] . According to Immunohistochemical staining results, breast cancer is categorized into different subtypes according to estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER)-2. Up to 80% of breast cancer cases are classified as ER-positive (ER + ), which highlights the significance of estrogen-related signaling in breast cancer [2, 3] . Currently, first-line salvage therapy for tamoxifen-resistant breast cancer patients includes fulvestrant (a selective ER down-regulator) [4, 5] , cyclin-dependent kinase 4/6 (CDK4/6) inhibitors [6] , aromatase inhibitors, everolimus (a mammalian target of rapamycin inhibitor) [7] , and histone deacetylase (HDAC) inhibitors [8] . However, resistance to these salvage therapies ultimately develops, and patients die from their cancer [9, 10] . Therefore, it is important to explore new effective therapeutics for ER + breast cancer patients. Coiled-coil domain (CCD) constituents are alpha-helix motifs expressed in different types of proteins. Owing to structural flexibility, they can function in various biological processes, including cell proliferation, migration, and signal transduction [11, 12] . In recent publications, CCD-containing (CCDC) proteins were aberrantly activated in multiple types of tumors, including CCDC178 in liver cancer, CCDC88A in pancreatic cancer, and CCDC8 in lung cancer [13] [14] [15] [16] [17] [18] . In addition, CCDC106 promotes the proliferation of lung cancer cell lines, and CCDC34 contributes to colorectal cancer development by inhibiting apoptosis signaling and promoting invasion [19] . Inhibition of CCDC69 increases platinum-induced apoptosis in A2780 ovarian cancer cells [20] . Knockdown of CCDC106 enhances apoptosis and suppresses growth of MCF7 breast cancer by stabilizing p53 [21] . However, there is yet little knowledge of the role of CCDC167 in breast cancer development.

Differential gene expression analyses in high-throughput techniques, such as RNA-sequencing (RNA-Seq), are performed by comparing gene expression profiles between two different conditions. The results define a set of genes with high expressions in cancer and low expressions in normal tissue through statistical tests [22] [23] [24] [25] [26] . However, in some particular circumstances, non-differentially expressed genes can contribute to disease dysfunction through clusters of co-expressed genes. These genes may manifest their functions through interaction networks with other differentially expressed genes. Therefore, expression signatures of these co-expressed genes might be crucial factors indirectly affecting the disease condition [27] [28] [29] [30] [31] . In the present study, we used a meta-analysis approach combined with a literature review to explore potential therapeutic targets in breast cancer. We systematically investigated messenger (m)RNA expression of CCDC167 and the survival probability of ER + breast cancer patients using a public high-throughput database. Meanwhile, we also investigated the effects of CCDC167 on the progression of breast cancer with an experimental approach.

Transcription expression levels of CCDC167 in 20 types of cancer were screened in the Oncomine database. The CCDC167 gene was upregulated in breast cancer compared to normal tissues in 12 studies AGING ( Figure 1A) . Furthermore, the GEPIA database was used to compare the CCDC167 gene in normal and cancerous tissues from 33 TCGA RNA-Seq datasets. We found that CCDC167 expression was upregulated in 18 of 33 datasets, including an invasive breast carcinoma (BRCA) dataset ( Figure 1B ). In the Richardson dataset, the CCDC167 gene and its co-expressed genes, such as SAC3D1, SPC24, CENPM and DEPDC1B, were substantially upregulated in breast ductal carcinoma compared to the normal group ( Figure 1C) . A similar expression profile of CCDC167 was also found in the METABRIC dataset for invasive ductal carcinoma versus normal breast tissues ( Figure 1D ) and other subtypes (Supplementary Figure 1) . Moreover, there have upregulated expression in various tissue types, and the color gradient represents a lower gene rank percentile. (B) CCDC167 expression level from 33 cancer datasets with transcripts per million (TPM) levels using the GEPIA database. Significant CCDC167 overexpression in cancers is highlighted in red, including the BRCA dataset, whereas downregulation is labeled in green. (C) Co-expression patterns of CCDC167 in the Oncomine database. CCDC167 is also called C6orf129. (D) CCDC167 expression was higher relative to normal breast tissues in the METABRIC database. (E) Correlations between CCDC167 and histological differentiation of breast cancer, with increasing expression levels of CCDC167 as tumors progressed from low to high grade.

AGING was a correlation between CCDC167 and histological differentiation of breast cancer, with increasing expression levels of CCDC167 as tumors progressed from nuclear grade I to III ( Figure 1E ). The bioinformatics analysis of breast cancer patient samples collectively provided clues to a potential role of CCDC167 during breast cancer development.

The role of CCDC167 in breast cancer has been less well studied, therefore, in the present study, we used coexpression analyses to reveal biological functions and information of possible mechanisms. Co-expression profiles of CCDC167 from breast cancers were identified in the METABRIC and TCGA databases. MetaCore analysis of GO enrichment was performed to predict gene functions and regulatory patterns ( Figure  2 ). We merged results from METABRIC and TCGA to obtain common co-expressed genes, which were then imported into the MetaCore platform. Results of pathway maps indicated that cell cycle-related signaling plays an essential role in breast cancer according to both databases (Supplementary Table 1 ). We discovered that genes co-expressed with CCDC167 also affected immune-and ubiquinone-related pathways, including "immune response antigen presentation by MHC class I", "immune response interferon (IFN)-alpha/beta signaling via phosphatidylinositol 3-kinase (PI3K) and nuclear factor (NF)-κB pathways", and "ubiquinone metabolism" in breast cancer.

In addition, from both TCGA and METABRIC databases, we found that "cell cycle role of the anaphase-promoting complex (APC) in cell cycle regulation" was the most significantly regulated pathway by CCDC167 co-expression in breast cancer ( Figure 3 ). We also identified several miRNAs through the miRWalk and IPA databases, including hsa-mir-760, hsa-mir-1193, hsa-mir-3960, hsa-miR-214-3p, hsa-miR-204-5p, hsa-miR-370-3p, hsa-miR-423-5p, and diagram circles represent co-expressed genes of CCDC167 from each database; the blue circle represents co-expressed genes in TCGA database, and the orange circle represents co-expressed genes in the METABRIC database. The MetaCore signaling pathway analysis demonstrated that the "cell cycle role of anaphase-promoting complex (APC) in cell cycle regulation" and cell cycle-related signaling (red rectangles) were significantly correlated with CCDC167 gene expression. Immune-response signaling is marked with blue rectangles, and ubiquinone metabolism is scored with red arrowheads.

AGING hsa-miR-744-5p, which may interact with CCDC167 ( Figure 4 ).

We further investigated the effect of increased expression of CCDC167 on carcinogenesis-related processes, such as proliferation, migration, and anchorage-independent growth. M10 (nontumorigenic), MCF-7 (ER + subtype), MDA-MB-231 (triple-negative subtype), and MDA-MB-468 (highly invasive) cell lines are widely used for breast cancer research, and they represent different subtypes [32, 33] . Therefore, we chose these four cell lines for further study. Endogenous levels of CCDC167 differed Figure 2 . These 945 genes were further exported to the MetaCore pathway analysis tool to identify gene networks and signaling pathways. The "cell cycle role of anaphase-promoting complex (APC) in cell cycle regulation" was the most significantly associated pathway. APC forms a complex with cell division cycle 20 (CDC20) or cadherin-1 (CDH1) to regulate the cell cycle.

AGING in a variety of breast cancer cell lines. We used a qPCR to detect CCDC167 mRNA levels, and results showed the highest expression of CCDC167 in MCF-7 cells compared to other breast cancer cell lines ( Figure 5A ). Plasmids of CCDC167-shRNA and the vector control from RNAi Core were transfected into the MCF-7 cell line. The knockdown efficiency of shRNA on exogenous CCDC167 was examined by a qPCR. A significant reduction in CCDC167 mRNA expression was observed upon transfection with the shCCDC167 plasmid ( Figure 5B ).

In order to investigate the anti-proliferative effect of CCDC167 shRNA on human breast MCF-7 cancer cells, we first measured its cell proliferation ability. The MTT assay detected differences in short-term cell proliferation between CCDC167-knockdown and control MCF-7 cells ( Figure 5C ). The long-term ability of cell proliferation was examined by a colonyformation assay. Long-term cell growth was suppressed in CCDC167-shRNA cells ( Figure 5D ), and the difference compared to control cells was significant ( Figure 5E ). Meanwhile, the ability to form colonies was higher in CCDC167-overexpressing MCF-7 cells, and the results confirmed that overexpression of CCDC167 promoted cell proliferation (Supplementary Figure 2A) . Knockdown of CCDC167 significantly altered cell cycle-related and apoptosis-related genes (Supplementary Figure 2B) . Percentages of both early and late apoptosis increased after CCDC167knockdown (Supplementary Figure 3) . Meanwhile, in order to investigate gene expressions of other CCDC family members in the METABRIC database, we also compared mRNA expression levels between different AGING subtypes of breast cancer including claudin-low, basal, Her2, luminal A, and luminal B relative to normal breast tissues (Supplementary Figures 4-10) . Several CCDC members were significantly overexpressed in breast cancer subtypes, which might imply the high impact of CCDC family genes on tumor development.

Fluorouracil (5-FU), carboplatin, paclitaxel, and doxorubicin are currently first-or second-line cytotoxic agents of adjuvant chemotherapy for breast cancer patients. Treatments with these compounds resulted in decreased cellular growth of MCF-7 cells ( Figure 6A ). Based on the qPCR results, we also found that treatment with these compounds also significantly decreased CCDC167 mRNA expression, which suggested that these drugs may downregulate CCDC167 signaling in breast cancer progression ( Figure 6B ).

We further analyzed CCDC167 overexpression in breast cancer patients ( Figure 6C ). Data on recurrence-free survival (RFS) and overall survival (OS) of breast cancer AGING patients were collected from the Kaplan-Meier Plotter database. High expression of CCDC167 was correlated with worse RFS and OS. High expression of CCDC167 was also correlated with RFS in the GSE25307 datasets [34] and disease-specific survival in the GSE3494 datasets [35, 36] . All of these results demonstrated that high expression of CCDC167 predicted poor prognoses.

Integrated analyses from this study showed that the CCDC167 expression level was higher in breast cancer. TCGA and METABRIC databases were used to analyze potentially CCDC167-co-expressed genes in breast cancer. We also used the MCF-7 breast cancer cell line and performed short-term and long-term cell proliferation assays to validate our bioinformatics pre-dictions. CCDC167 expression has the potential to predict the survival of breast cancer patients and provide targets for further therapy. To the best of our knowledge, the present study is the first to provide comprehensive evidence of a novel association between CCDC167 and the prognosis of breast cancer patients.

The differential co-expression concept is related to genegene comparisons between two conditions, such as cancer and normal tissues. It implies that any alterations detected by conventional methods for differentially expressed genes might do not be beneficial if some genes not pass the differential threshold. However, insignificant changes in these genes could indirectly affect the regulatory system due to their co-expressed genes [37] [38] [39] . These differentially co-expressions could contribute to the disease without changing their expression levels. These differentially co-expressed genes and their AGING associated disease can be revealed using gene-gene correlations between cancer and normal tissues. This information could potentially be useful in combination with conventional analyses of differential expression patterns. In addition, it could help identify underlying mechanisms in a biological system under different conditions. Detailed mechanisms of the CCDC167 gene in breast cancer were explored by examining its coexpressed genes from TCGA and METABRIC databases. Afterward, GeneGo and MetaCore annotations for enriched biological processes indicated that CCDC167co-expressed genes were involved in cell cycle-related molecular processes. Next, in order to validate our bioinformatics predictions, we measured the ability of cells to proliferate with both a short-term MTT assay and a long-term colony-formation assay. MCF-7 shCCDC167 cells exhibited a significantly lower ability of cell proliferation compared to vector control cells.

Furthermore, we found that CCDC167-co-expressed genes were also involved in cell cycle and ubiquitination pathways, highlighting their essential roles in breast cancer. Cell division progression, ubiquinone metabolism, initiation of mitosis, spindle assembly, and chromosome separation were all topranked pathways of CCDC167-co-expressed genes. These results were found in the METABRIC and TCGA-BRCA datasets, and the findings were consistent across different populations. CCDC167-co-expressed genes were involved in the cell cycle, immune response, and ubiquitination-related pathways. CCDC167 also cooperated with several miRNA and oncogenic signaling pathways. The high expression of CCDC167 in breast cancer patients was also correlated with worse survival in these public databases. All of these data implicated the significance of CCDC167 in the progression of breast cancer. 5-FU, carboplatin, paclitaxel, and doxorubicin have the ability to inhibit breast cancer cell growth. These US FDA-approved compounds are currently first-or second-line regimens for postoperative adjuvant chemotherapy of breast cancer patients. We also found that treatment with fluorouracil, carboplatin, paclitaxel, and doxorubicin resulted in decreased expression of CCDC167 and suppressed growth of MCF-7 cells; these data suggested that CCDC167 signaling might be a critical target for these cytotoxic drugs. Other compounds that act against CCDC167 could be new therapeutic agents for treating breast cancer patients.

In conclusion, the present study demonstrated the crucial roles played by CCDC167 and its downstream signaling in breast cancer patients. These CCDC167-related pathways could potentially be targeted for treating and preventing breast cancer. The current study focused on CCDC167 pathways and cell cycle-related signatures, and these findings suggest that CCDC167 could have high potency as targeted therapy for breast cancer.

MCF-7 cells were grown in 10% fetal bovine serum (FBS) supplemented with Dulbecco's modified Eagle's medium (DMEM). The ability for short-term cell proliferation was examined by an MTT assay. A colonyformation assay was utilized to evaluate the ability of long-term cell proliferation. MCF-7 cells were trypsinized and seeded in six-well plates at a low density of 500 cells/well and grown in the presence of US Food and Drug Administration (FDA)-approved drugs predicted from a bioinformatics analysis [40] [41] [42] [43] [44] [45] . After 2 weeks, the medium was aspirated from the six-well plates, and MCF-7 cells were fixed with methanol. Then, 0.1% crystal violet in distilled water was added to each well for 10 min to stain the colonies. After the crystal violet solution was removed, the plates were washed with distilled water five times and air-dried. Colonies in each well were enumerated under low-magnification light microscopy.

We used TRIzol reagent (Invitrogen, Carlsbad, CA, USA) for total RNA extraction from MCF-7 cells following a datasheet. Next, a cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) was used for reverse transcription of total RNA (1 µg) to complementary (c)DNA. A real-time PCR with the FastStart Universal SYBR Green Master (Roche, Basel, Switzerland) kit was conducted with 5% of each cDNA as the template with the ABI Step One Plus system (Applied Biosystems). Each experiment was repeated three times, and all results were normalized to GAPDH [46] [47] [48] [49] [50] [51] . For small hairpin (sh)RNA-mediated signaling, shRNAs targeting CCDC167 and vector control were purchased from the National RNAi Core Facility (Academia Sinica, Taipei 

For the cell cycle assay, CCDC167 knockdown MCF-7 cells and the parental cells were grown in 10 cm dish, then we used trypsin to isolate cell. Next, the cells were centrifuged for 5 min at 1000×g, fixed with 70 % alcohol as well as ice-cold PBS, and incubated at 40° C for a minimum of 30 min. RNase (Takara, Shiga, Japan) was added to the samples within 30 min at room temperature. The propidium iodide (PI) solution and Annexin V-FITC Apoptosis Kit (AAT Bioquest, Inc. CA, USA) and was used for cell cycle experiments. All samples were analyzed using flow cytometry (FACS Calibur; BD Biosciences, San Jose, CA, USA) with a counting threshold of 10 6 cells.

Transcriptomics expression levels of CCDC167 in multiple types and subtypes of cancers were screened in the Oncomine database with public high-throughput datasets using differential analysis options for cancer versus normal samples in the primary filters [52] . The method was clearly described in our previous studies [53] [54] [55] [56] [57] . Briefly, the thresholds for p values, multiples of change, and gene rank percentiles were set to 0.001, 1.5, and the top 10%, respectively. For the co-expression analysis, we selected breast cancer-related datasets which satisfied the thresholds mentioned above. The dataset with the highest correlation score was selected for analysis of genes co-expressed with CCDC167. In addition to the Oncomine database, we also used the GEPIA to analyze mRNA expression levels of CCDC167 in 33 datasets available in The Cancer Genome Atlas (TCGA) database [58] . CCDC167 expression levels were compared between tumor and normal groups, and these comparisons are illustrated in a dot plot with a log2 scale of transcripts per million (TPM) [59] .

The RNA-Seq dataset from TCGA [60] and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [61] were retrieved from the cBioPortal [62] . Normalized expression data were used to obtain the top 10% co-expressed genes based on CCDC167 expression, and a Venn diagram was plotted to determine genes highly correlated with CCDC167. Finally, these co-expressed genes were further analyzed using networks and pathways. The molecular functions and disease pathways of Gene Ontology (GO) terms in MetaCore (GeneGo, St. Joseph, MN, USA) were used to screen and analyze signaling networks in these breast cancer patients [63] [64] [65] [66] . A p value of <0.05 represented statistical significance. To search for CCDC167associated miRNAs, we used miRWalk 2.0 to predict potentially regulated miRNAs. Based on the miRmap score, which was calculated as the repressive strength of miRNA binding to its target mRNA, we chose a cutoff of the miRmap score of >99 for inclusion in our study and analyzed regulated pathways and networks with an Ingenuity Pathway Analysis (IPA).

Expression data from CCDC family genes were collected from the METABRIC database and plotted with a violin plot for comparisons among different molecular subtypes, including basal, claudin-low, HER-2, luminal A, luminal B, and normal-like breast cancers. Plots were conducted with R studio vers. 1.2.1335 under R vers. 4.0.3 using the ggpubr package vers. 0.4.0 [67] .

Correlations of mRNA expression levels of CCDC167 and breast cancer patient survival were analyzed using the Kaplan Meier-plot database [68] . In brief, distant metastasis-free survival (DMFS) was selected for CCDC167 with all default settings of the Kaplan Meier-Plot database to obtain the survival curve. In addition, survival data of the GSE25307 and GSE3494-GPL97 AGING datasets were downloaded from the NCBI GEO and PrognoScan databases, and the survival risk was calculated using the Kaplan-Meier method with the log-rank test.

All results are reported as the mean ± standard deviation (SD) with three or more replicates. Student's t-test was used to calculate differences between groups with p<0.05 accepted as significant. 

Cancer statistics, 2020

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Challenges in Treating Estrogen Receptor-Positive Breast Cancer

Targeting the cyclindependent kinases (CDK) 4/6 in estrogen receptorpositive breast cancers

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Impacts of cytochrome P450 2D6 (CYP2D6) genetic polymorphism in tamoxifen therapy for breast cancer

PKD1 interacts with PKD2 through a probable coiled-coil domain

CARMA1 coiledcoil domain is involved in the oligomerization and subcellular localization of CARMA1 and is required for T cell receptor-induced NF-kappaB activation

CCDC178 promotes hepatocellular carcinoma metastasis through modulation of anoikis

CCDC88A, a prognostic factor for human pancreatic cancers, promotes the motility and invasiveness of pancreatic cancer cells

Coiled-coil domain-containing protein 8 inhibits the invasiveness and migration of non-small cell lung cancer cells

Identification of potential crucial genes and key pathways in breast cancer using bioinformatic analysis

Neurexophilin and PC-esterase domain family member 4 (NXPE4) and prostate androgen-regulated mucin-like protein 1 (PARM1) as prognostic biomarkers for colorectal cancer

Effects of CORO2A on cell migration and proliferation and its potential regulatory network in breast cancer

Overexpression of CCDC34 in colorectal cancer and its involvement in tumor growth, apoptosis and invasion

Inhibition of coiled coil domain containing protein 69 enhances platinum-induced apoptosis in ovarian cancer cells

CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression

RNA-sequencing analyses of small bacterial RNAs and their emergence as virulence factors in host-pathogen interactions

In vitro zika virus infection of human neural progenitor cells: meta-analysis of RNA-seq assays

Molecular characteristics of uveal melanoma: insights from the cancer genome atlas (TCGA) project. Cancers (Basel)

Gene signatures and prognostic analyses of the Tob/BTG pituitary tumor-transforming gene (PTTG) family in clinical breast cancer patients

LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target

LncRNA profile study reveals a three-LncRNA signature associated with the pathological complete response following neoadjuvant chemotherapy in breast cancer

Gene expression and methylation profiles identified CXCL3 and CXCL8 as key genes for diagnosis and prognosis of colon adenocarcinoma

Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer

Knockdown of serine/threonine-protein kinase 24 promotes tumorigenesis and myeloid-derived suppressor cell expansion in an orthotopic immunocompetent gastric cancer animal model

Optimization protein productivity of human interleukin-2 through codon usage, gene copy number and intracellular tRNA concentration in CHO cells

Assessing metastatic potential of breast cancer cells based on EGFR dynamics

PODXL2 maintains cellular stemness and promotes breast cancer development through the Rac1/Akt pathway

The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer

An HIF-1α/VEGF-a axis in cytotoxic T cells regulates tumor progression

Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts

Gene coexpression network analysis reveals common systemlevel properties of prognostic genes across cancer types

Computational analysis for identification of the extracellular matrix molecules involved in endometrial cancer progression

Gene co-expression analysis for functional classification and gene-disease predictions

Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer

Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer

A gene expression signature-based approach reveals the mechanisms of action of the Chinese herbal medicine berberine

Systematic polypharmacology and drug repurposing via an integrated L1000-based connectivity map database mining

The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG

In silico and in vitro identification of inhibitory activities of sorafenib on histone deacetylases in hepatocellular carcinoma cells

MST3 promotes proliferation and tumorigenicity through the VAV2/Rac1 signal axis in breast cancer

Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin

A novel cancer therapeutic using thrombospondin 1 in dendritic cells

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model

Homoharringtonine induced immune alteration for an efficient anti-tumor response in mouse models of nonsmall cell lung adenocarcinoma expressing kras mutation

MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy

ONCOMINE: a cancer microarray database and integrated data-mining platform

PSMB5 plays a dual role in cancer development and immunosuppression

Mutation of the PTCH1 gene predicts recurrence of breast cancer

Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence

Cancer-derived transforming growth factor-β modulates tumorassociated macrophages in ampullary cancer

Endovascular biopsy: in vivo cerebral aneurysm endothelial cell sampling and gene expression analysis

Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons' Data

GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

Gene signatures of SARS-CoV/SARS-CoV-2-infected ferret lungs in short-and long-term models

Single-cell RNA sequencing reveals gene expression signatures of breast cancer-associated endothelial cells

The novel regulations of MEF2A, CAMKK2, CALM3, and TNNI3 in ventricular hypertrophy induced by arsenic exposure in rats

Novel therapeutic effects of sesamin on diabetes-induced cardiac dysfunction

Package 'ggpubr

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

The authors give special thanks to Prof. Ju-Ming Wang from National Cheng Kung University for his technical support, and we would like to thank Mr. Daniel P. Chamberlin for his professional English editing from the Office of Research and Development at Taipei Medical University.

The authors declare no conflicts of interest.